| Astron Corporation Limited (ATR) ORDINARY FULLY PAID |
Materials |
$271 |
Updated Donald Project Economics - Phase 1
|
23 Jul 2025 8:34AM |
$0.785 |
$0.630 |
fallen by
19.75%
|
|
ATR - Price-sensitive ASX Announcement
Full Release
Key Points
- Astron Corporation Limited released an updated economic assessment for Phase 1 of the Donald Rare Earth and Mineral Sands Project.
- The project is located in Victoria, Australia, and contains significant reserves of rare earth elements and mineral sands.
- Key improvements include increased project NPV and IRR, along with a reduction in the payback period.
- Updates are based on revised capital and operating costs, updated product pricing, and changes to the mining schedule.
- The revised assessment reflects market outlook and cost assumptions as of June 2023.
- The report highlights the strategic importance of the Donald Project for global supply of critical minerals.
- Astron aims to advance the project to meet growing demand for rare earths and minerals essential to advanced technologies and clean energy industries.
- The company is continuing to optimize and de-risk the project as it proceeds towards development and financing.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Barton Gold Holdings Limited (BGD) ORDINARY FULLY PAID |
Materials |
$208 |
Presentation to Noosa Mining Conference
|
23 Jul 2025 8:34AM |
$0.710 |
$0.770 |
risen by
8.45%
|
|
| QPM Energy Limited (QPM) ORDINARY FULLY PAID |
Materials |
$36 |
TPS Update
|
23 Jul 2025 8:32AM |
$0.037 |
$0.009 |
fallen by
75.68%
|
|
| Atturra Limited (ATA) ORDINARY FULLY PAID |
Information Technology |
$173 |
Update - Notification of buy-back - ATA
|
23 Jul 2025 8:32AM |
$0.850 |
$0.470 |
fallen by
44.71%
|
|
| Great Boulder Resources Limited (GBR) ORDINARY FULLY PAID |
Materials |
$142 |
Noosa Mining Conference presentation
|
23 Jul 2025 8:31AM |
$0.063 |
$0.072 |
risen by
14.29%
|
|
| Nyrada Inc (NYR) CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED |
Health Care |
$104 |
NYR Advances Xolatryp Phase IIa Trial in Cardioprotection
|
23 Jul 2025 8:30AM |
$0.350 |
$0.420 |
risen by
20%
|
|
NYR - Price-sensitive ASX Announcement
Full Release
Key Points
- Nyrada Inc advances Xolatryp Phase IIa clinical trial in cardioprotection.
- The trial focuses on reducing cardiac damage during procedures that can cause myocardial injury.
- Xolatryp is a novel, first-in-class therapeutic candidate developed by Nyrada Inc.
- Previous preclinical and Phase I studies have been successfully completed.
- The company has secured regulatory approvals to commence the Phase IIa trial.
- Patient recruitment for the trial has begun.
- Xolatryp addresses an unmet need in cardiovascular medicine, specifically for cardioprotection.
- The trial will assess safety, pharmacokinetics, and preliminary efficacy endpoints.
- Nyrada Inc aims to reduce the global burden of cardiovascular disease through novel treatments.
- Xolatryp may represent a breakthrough in protecting heart tissue from ischemic damage.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ampol Limited (ALD) ORDINARY FULLY PAID |
Energy |
$8,288 |
Growing Fuel and Convenience Earnings
|
23 Jul 2025 8:30AM |
$26.890 |
$34.780 |
risen by
29.34%
|
|
ALD - Price-sensitive ASX Announcement
Full Release
Key Points
- Ampol Limited (ASX:ALD) reported a Group Replacement Cost Operating Profit (RCOP) EBITDA of ~$640 million for the first half of the 2025 financial year.
- Convenience Retail segment showed growth in EBIT, driven by a favorable mix of premium fuels.
- New Zealand segment achieved modestly higher EBIT due to diversified market channels.
- Fuels & Infrastructure (F&I) Australia EBIT was similar to the previous year, with supply chain impacts mitigated by better margins in middle distillates.
- F&I International operations remained at breakeven, focusing on supply within the Ampol system.
- Lytton refinery's EBIT was around breakeven, supported by improved Lytton Refiner Margin.
- Ampol's interest expense and effective tax rate are expected to remain favorable.
- Further audited financial results will be released on 18 August 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ampol Limited (ALD) ORDINARY FULLY PAID |
Energy |
$8,288 |
Growing Fuel and Convenience Earnings
|
23 Jul 2025 8:30AM |
$26.890 |
$34.780 |
risen by
29.34%
|
|
ALD - Price-sensitive ASX Announcement
Full Release
Key Points
- Ampol Limited reported a Group RCOP EBITDA of ~$640 million and RCOP EBIT of ~$400 million for the first half of 2025.
- Convenience Retail continued its trend of growing earnings, driven by a favorable mix of premium fuels.
- New Zealand segment achieved modest EBIT growth, benefiting from diversified market channels.
- Fuels & Infrastructure (F&I) Australia maintained EBIT levels comparable to the previous year.
- Lytton refinery's EBIT was around breakeven in the first half of 2025, supported by an improved Lytton Refiner Margin.
- The interest expense for 1H 2025 is expected to be in line with the prior period.
- Convenience Retail’s U-GO expanded to 34 sites in Australia.
- Overall Group sales volume decreased by 6.1% year-on-year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Racura Oncology Ltd (RAC) ORDINARY FULLY PAID |
Health Care |
$416 |
June 2025 Quarterly Activity Report and Appendix 4C
|
23 Jul 2025 8:28AM |
$1.140 |
$2.120 |
risen by
85.96%
|
|
RAC - Price-sensitive ASX Announcement
Full Release
Key Points
- Report covers the quarter ending June 2025 for Race Oncology Ltd.
- Highlights significant clinical and preclinical progress, especially with bisantrene.
- Details updates on ongoing and planned clinical trials.
- Mentions collaborations with international research institutions.
- Provides regulatory and intellectual property developments.
- Appendix 4C includes a summary of cash receipts, expenditures, and end-of-quarter cash balance.
- Company maintains a strong focus on advancing its lead drug candidate.
- Operational activities are aligned with research and development goals.
- Financial position detailed in Appendix 4C supports ongoing business activities and research programs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Scentre Group (SCG) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$20,161 |
DXS:DWSF Westfield Chermside investment and DXS transactions
|
23 Jul 2025 8:27AM |
$3.730 |
$3.860 |
risen by
3.49%
|
|
| Dexus (DXS) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$6,060 |
DWSF Westfield Chermside investment and DXS transactions
|
23 Jul 2025 8:27AM |
$7.050 |
$5.650 |
fallen by
19.86%
|
|
| Westpac Banking Corporation (WBC) ORDINARY FULLY PAID |
Financials |
$123,986 |
Update - Notification of buy-back - WBC
|
23 Jul 2025 8:27AM |
$32.650 |
$36.250 |
risen by
11.03%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$33 |
Completion of Recruitment in TRIPP-FFX Clinical Trial
|
23 Jul 2025 8:27AM |
$1.185 |
$1.080 |
fallen by
8.86%
|
|
OSL - Price-sensitive ASX Announcement
Full Release
Key Points
- Oncosil Medical Limited has completed recruitment for the TRIPP-FFX clinical trial.
- The TRIPP-FFX trial investigates the OncoSil™ device in combination with FOLFIRINOX for locally advanced pancreatic cancer.
- A total of 71 patients have been enrolled in the study.
- Clinical sites for the trial are located internationally.
- Completion of recruitment marks a major milestone in the company’s clinical program.
- The next steps involve data analysis and preparation for regulatory and commercial processes.
- The OncoSil™ device is designed to deliver targeted radiation directly to pancreatic tumors.
- The company acknowledges the contribution of patients, investigators, and clinical teams.
- Further updates will be provided as trial data becomes available.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sovereign Metals Limited (SVM) ORDINARY FULLY PAID |
Materials |
$361 |
DFS Progressing Well with Completion of Geotechnical Program
|
23 Jul 2025 8:26AM |
$0.760 |
$0.550 |
fallen by
27.63%
|
|
| Westgold Resources Limited (WGX) ORDINARY FULLY PAID |
Materials |
$4,469 |
Q4, FY25 Webcast Presentation
|
23 Jul 2025 8:25AM |
$2.860 |
$4.730 |
risen by
65.38%
|
|
| Galileo Mining Ltd (GAL) ORDINARY FULLY PAID |
Materials |
$21 |
Norseman PGE Project Drill Program in Progress
|
23 Jul 2025 8:24AM |
$0.165 |
$0.105 |
fallen by
36.36%
|
|
GAL - Price-sensitive ASX Announcement
Full Release
Key Points
- Galileo Mining Ltd is advancing drilling activities at the Norseman PGE Project.
- The program targets nickel, copper, and cobalt mineralization with a focus on the Callisto discovery.
- Reverse circulation (RC) and diamond drilling methods are being utilized across multiple prospects.
- Early drill results are positive, with further assay results pending.
- Geological and geophysical data are being used to guide the exploration strategy.
- The company is systematically exploring for PGE-nickel-copper sulphide mineralization.
- Future exploration plans are underway to expand on current discoveries.
- The drill program is part of a broader strategy for resource development at Norseman.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| L1 Long Short Fund Limited (LSF) ORDINARY FULLY PAID |
Financials |
$2,932 |
Net Tangible Asset Backing
|
23 Jul 2025 8:22AM |
$3.000 |
$4.620 |
risen by
54%
|
|
| Westgold Resources Limited (WGX) ORDINARY FULLY PAID |
Materials |
$4,469 |
June 2025 Quarterly Results
|
23 Jul 2025 8:22AM |
$2.860 |
$4.730 |
risen by
65.38%
|
|
WGX - Price-sensitive ASX Announcement
Full Release
Key Points
- Record gold production of 88,022 ounces achieved in Q4 FY25.
- All-In Sustaining Cost (AISC) for Q4 FY25 was $237 million, equating to $2,688 per ounce.
- Westgold Resources Limited announced a maiden Mineral Resource Estimate of 2.3 million ounces for the Fletcher Zone at Beta Hunt.
- Total cash, bullion, and investments increased to $364 million by the end of Q4 FY25.
- Westgold remains 100% unhedged and achieved an average gold price of $5,174 per ounce in Q4 FY25.
- Capital expenditure for Q4 FY25 totaled $39 million, primarily invested in growth projects and equipment.
- Westgold's net mine cashflow for Q4 FY25 was $171 million.
- Mining rates improved quarter on quarter in key operations including Bluebird-South Junction.
- The company plans to release FY26 guidance in August and a 3-year outlook in September FY26.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Westgold Resources Limited (WGX) ORDINARY FULLY PAID |
Materials |
$4,469 |
June 2025 Quarterly Results
|
23 Jul 2025 8:22AM |
$2.860 |
$4.730 |
risen by
65.38%
|
|
WGX - Price-sensitive ASX Announcement
Full Release
Key Points
- Record gold production of 88,022 ounces in Q4 FY25.
- Achieved gold price of $5,174 per ounce.
- Revenue generated was $370 million for the quarter.
- Strong cash position of $364 million at the end of Q4 FY25.
- Investments in growth projects and exploration totaled $39 million and $9 million respectively.
- Safety performance improved, with a reduced Total Recordable Injury Frequency Rate.
- Maiden Mineral Resource Estimate of 2.3Moz announced for the Fletcher Zone at Beta Hunt.
- Westgold remains unhedged, fully exposed to the spot gold price.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Mitchell Services Limited (MSV) ORDINARY FULLY PAID |
Materials |
$104 |
Quarterly Investor Update
|
23 Jul 2025 8:18AM |
$0.300 |
$0.490 |
risen by
63.33%
|
|
MSV - Price-sensitive ASX Announcement
Full Release
Key Points
- MSV reported strong revenue and EBITDA for the March 2024 quarter.
- The company has secured several new contracts and contract extensions, underpinning future revenue.
- Mining sector demand for drilling services remains high, supporting elevated fleet utilisation rates.
- Workforce numbers have increased to meet operational requirements.
- Strategic investment in fleet upgrades and technology continues to drive efficiency and competitiveness.
- Safety performance remains a central focus, with ongoing improvements and initiatives.
- Management commentary addresses current market conditions and operational challenges.
- The report includes summaries of financial performance and outlook statements for upcoming quarters.
- Investor relations contacts and company information are provided.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bubalus Resources Limited (BUS) ORDINARY FULLY PAID |
Materials |
$5 |
Compelling Fosterville-Style Targets at Crosbie North
|
23 Jul 2025 8:18AM |
$0.091 |
$0.075 |
fallen by
17.58%
|
|
BUS - Price-sensitive ASX Announcement
Full Release
Key Points
- Bubalus Resources Limited has identified a high-priority Fosterville-style gold target at Crosbie North in Western Australia.
- The target zone is defined by significant arsenic and antimony anomalies, which are key pathfinder elements for gold mineralization.
- Geochemical and structural signatures at Crosbie North are considered analogous to those found at the Fosterville Gold Mine.
- The company plans to conduct further geophysical surveys and follow-up drilling to test the new targets.
- The Amadeus Project's geological setting is favorable for the discovery of high-grade gold mineralization.
- Future work will focus on refining targets and advancing exploration to unlock the project's potential.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$6 |
HITIQ Appoints Nathan Murphy as Brand Ambassador
|
23 Jul 2025 8:18AM |
$0.020 |
$0.006 |
fallen by
70%
|
|
| Regal Asian Investments Limited (RG8) ORDINARY FULLY PAID |
Financials |
$401 |
Update - Notification of buy-back - RG8
|
23 Jul 2025 8:18AM |
$2.030 |
$2.840 |
risen by
39.90%
|
|
| Orica Limited (ORI) ORDINARY FULLY PAID |
Materials |
$10,944 |
Update - Notification of buy-back - ORI
|
23 Jul 2025 8:18AM |
$21.270 |
$23.610 |
risen by
11%
|
|
| Plenti Group Limited (PLT) ORDINARY FULLY PAID |
Financials |
$137 |
1Q26 update - another record quarter
|
23 Jul 2025 8:17AM |
$0.930 |
$0.750 |
fallen by
19.35%
|
|
PLT - Price-sensitive ASX Announcement
Full Release
Key Points
- Loan originations reached $581 million in 1Q26, up 24% year-on-year.
- Total loan portfolio grew to $2.3 billion, marking continued portfolio expansion.
- Revenue for the quarter increased by 36% to $59 million.
- Automotive and renewable energy lending were the primary growth drivers.
- Credit quality remained robust with net losses and arrears below historical averages.
- Plenti reaffirmed its FY26 guidance for growth and profitability.
- Ongoing investment in technology, product innovation, and partnerships supported performance.
- Market share gains were achieved across target lending verticals.
- Funding position remains strong, supporting further growth ambitions.
- Focus on operational efficiency and cost discipline continues.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
